Clinical Trial Update: Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants [Phase 1]

View source ↗

Summary

This report covers completion of a Phase 1 trial evaluating adverse events and pharmacokinetics of ABBV-932 oral capsules in healthy adult participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• ABBV-932

Snippet

Sponsor: AbbVie | Conditions: Generalized Anxiety Disorder (GAD), Healthy Participants | Phase 1 | Status: COMPLETED